Evidence map›Paper›PMID 41544221›Full record

ArticleBlood advances2026

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Tiana Kordbacheh, Kelvin K W Chan, Michael Crump, Zharmaine Ante, Ning Liu, Mahmood Aminilari, Inna Y Gong, Sita Bhella, Abi Vijenthira, John Kuruvilla and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tiana KordbachehDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Kelvin K W ChanDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Michael CrumpDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Zharmaine AnteICES, Toronto, ON, Canada.
Ning LiuICES, Toronto, ON, Canada.ORCID 0000-0001-9215-475X
Mahmood AminilariRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0002-0517-9666
Inna Y GongDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Sita BhellaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Abi VijenthiraDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
John KuruvillaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Robert KridelDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-0287-7124
Christine ChenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Vishal KukretiDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Chloe YangDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
David HodgsonRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0003-4687-4582
Anca PricaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Danielle RodinRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0001-8279-0621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractAnti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapies have been funded in Canada for relapsed/refractory large B-cell lymphoma (R/R-LBCL) after 2 lines of systemic therapy since late 2019. Real-world outcome data have been limited by lack of comparison to historical care. Using propensity-weighted analysis, we compared 3-year survival, health care resource use (HRU), and hospitalization events for patients with R/R-LBCL treated with CAR-T (n = 85) vs historical controls (HCs) treated before CAR-T approval who would have been eligible based on present criteria (n = 150). CAR-T 3-year overall survival (OS) was 59% (95% confidence interval [CI], 42-72; median, not reached) vs 10% (95% CI, 5-16; median, 4.4 months) in HCs. Three-year CAR-T progression-free survival (PFS) was 48% (95% CI, 32-63]; median, 14.4 months) vs 6% (95% CI, 3-11; median, 3.6 months) in HCs. The hazard ratio (HR) for OS was 0.21 (95% CI, 0.14-0.31), and for PFS was 0.28 (95% CI, 0.2-0.39), comparing CAR-T vs HCs. Per 1000 person-days at risk, patients receiving CAR-T had fewer hospital admissions than HCs (5.32 vs 9.1), emergency visits (2.33 vs 4.81), and intensive care admissions (0.53 vs 1.25), plus lower hospitalization rates for fever (0.93 vs 1.63), infection (1.48 vs 3.08), and neutropenia (0.66 vs 1.97; all P< .001). CAR-T produced a sustained survival benefit, and, despite well-described CAR-T toxicities, HCs experienced more hospitalization events, underscoring the lack of effective salvage treatments. As one of the largest real-world comparisons of patients with R/R-LBCL receiving CAR-T vs previous standard of care, this study demonstrated its improved effectiveness and reduced HRU.

Indexed as

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseAdultAgedFemaleHumansMaleMiddle AgedTreatment Outcome

Identifiers

PMID41544221
PMCPMC13066962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.